ФИБРОЗ ПЕЧЕНИ: МЕХАНИЗМЫ И МЕТОДЫ ТЕРАПИИ

  • А. Т. Фиясь (A. T. Fiyas) Гродненский государственный медицинский университет http://orcid.org/0000-0002-7551-022X
  • Н. Ф. Василевская (N. F. Vasilevskaya) Гродненская университетская клиника https://orcid.org/0000-0001-9345-7373
  • Е. Ф. Пищик (E. F. Pishchyk) Гродненская университетская клиника https://orcid.org/0000-0002-1392-3846
Ключевые слова: экстрацеллюлярный матрикс, цитокины, фиброгенез, антикоагулянты

Аннотация


В обзоре приведены данные по механизмам развития фиброза при хронических заболеваниях печени с учетом различных механизмов процесса, по влиянию молекулярных, нейротрофических, генетических факторов, цитокинов на процесс фиброзирования. Приведены современные рекомендации по разным вариантам антифибротической и антикоагулянтной терапии с учетом основных этиопатогенетических факторов фиброзирования печени.

Литература


1. Ahmad A, Ahmad R. Understanding the Mechanism of Hepatic Fibrosis and Potential Therapeutic Approaches. Saudi J Gastroenterol. 2012;18(3):155-167. doi: 10.4103/1319-3767.96445.


2. Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Phisiol Gastrointest Liver Phisiol. 2011;301(6):G950-G955. doi: 10.1152/ajpgi. 00132.2011.


3. Seile R, Di Rosso P, Dudas J, El-Armouche H, Sebb H, Eisenbach С, Neubauer К, Ramadori G. IGF-1 induces DNA synthesis and apoptosis in rat liver hepatic stellate cells (HSC) proliferation in rat liver myofibroblasts (rMF). Lab Invest. 2004;94:1037-1049.


4. Gassuli X, Bataller R, Gines P, Sancho-Bru P, Nicolas JM, Gorbig MN, Ferrer E, Badia E, Gual A, Arroyo V, Rodes J. Human myofibroblastic hepatic stellate cells expressed Ca2+ activated K+ channels that modulate the effects of endothelin-1 and nitric oxide. J Hepatol. 2001;35:739-748. doi: 10.1016/s0168-8278(01)00198-2.


5. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther Adv Gastroenterol. 2011;4(6):391-417. doi: 10.1177/175683X11413002.


6. Iredale P, Benyan RC, Pickering J, McCulien M, Northrop M, Pawley S, Hoveii C, Arthur MJ. Mechanisms of spontaneous resolution of fat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Investig. 1998;102(3):538-549. doi: 10.1172/JCI1018.


7. Bataller R, Brenner DA. Liver fibrosis. J Clin Investig. 2005;115(2):209-218. doi: 10.1172/jci20054248.


8. Nie QH, Duan GR, Lou XD, Xie YM, Luo H, Zhou YX, Pan BR. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol. 2004;10(1):86-89. doi: 10.3748/wjg.v10.i1.86.


9. Lakner AM, Stenerwald NM, Walling TI, Chosh S, Li T, McKillop IH, Russo MW, Bonkovsky HL, Schrum LW. Inhibitory effect of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology. 2012;56(1):300-310. doi: 10.1002/hep.25613.


10. Wheeler VD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, Gabele E, Rysyn I, Yamashina S, Froh M, Adachi Y, Limuro Y, Bradford BU, Smutney OM, Connor HD, Mason RP, Goyert SM, Peters JM, Gonzalez FJ, Samulski RJ, Thurman RG. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol. 2001;31(12):1544-1549. doi: 10.1016/S0891-5849(01)00748-1.


11. Li Z, Oben JA, Yang S, Stafford EA, Soloski MJ, Thomas SA, Diehl AM. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology. 2004;40(2):434-441. doi: 10.1002/hep.20320.


12. Gao R, Radaeva S, Park O. Liver natural killer T-cells: immunobiology and emerging roles in liver diseases. J Leukos Biol. 2009;86(3):513-528. doi: 10.1189/JLB.0309135.


13. Mallat A, Teixeira-Clere E, Letersztain S. Cannabinoid signaling and liver therapeutic. J Hepatol. 2013;59(4):891-896. doi: 10.1016/j.jhep.2013.03.032.


14. Elpek GO. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol. 2014;20(23):7250-7276. doi: 10.3748/wjg.v20.i23.7260.


15. Lin T, Wang P, Cong M, Xu Y, Jia J, You H. The CYP2E1 inhibitor DDC up-regulates MMP-1 expression in hepatic stellate cells via an ERK1/2 and Akt-dependent mechanism. Bioch Rep. 2013;33(3):е00041. doi: 10.1042/BSR20130033.


16. Cheng JY-K, Wong GL-H. Advances in the diagnosis and treatment of liver fibrosis. Hepatoma Res. 2017;3:156-169. doi: 10.20517/2394-5079.2017.27.


17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64(1):179-201. doi: 10.1016/j.jhep.2015.07.040.


18. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J. Hepatol. 2010;53(1):132-144. doi: 10.1016/j.jhep.2010.02.027.


19. Wu JR, Hu CT, You RI, Pan SM, Cheng CC, Lee MC, Wu CC, Chang YJ, Lin SC, Chen CS, Lin TY, Wu WS. Hydrogen peroxide inducible clone-5 mediates reactive oxygen species signaling for hepatocellular carcinoma progression. Oncotarget. 2015;6(32):32526-32544. doi: 10.18632/oncotarget.5322.


20. Dhar A, Mullish BH, Thursz MR. Anticoagulation in chronic liver disease. J. Hepatol. 2017;66(6):1313-1324. doi: 10.1016/j.jhep.2017.01.006.


21. Bogari H, Patanwala AE, Cosgrave R, Katz M. Risk assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. Thromb Res. 2014;134(6):1220-1223. doi: 10.1016/j.thromres. 2014.09.031.


Просмотров аннотации: 78
Загрузок PDF: 46
Опубликован
2019-12-17